Merck's diabetes blockbuster Januvia boards pay-for-performance train with Aetna deal

Januvia box

Add Merck to the list of companies participating in pay-for-performance deals. Facing stepped-up competition in diabetes, the pharma signed a value-based contract with leading insurer Aetna on its blockbuster meds Januvia and Janumet.

Through the deal, the drugs’ effectiveness in managing Type 2 diabetes for Aetna’s patients will partially determine rebates.

For Januvia, the arrangement could provide a boost in the face of new launches in the GLP-1 and SGLT2 drug classes. The pact comes on the heels of a performance-based partnership between Eli Lilly & Co. and Harvard Pilgrim for the weekly GLP-1 med Trulicity.


Survey: The Critical Role of Innovation in Launching Successful OTC Products

This research aims to understand the importance of product innovation and dose forms in driving new product design and development, consumer engagement and purchase interest for Over-the-Counter medicines. The first 50 qualified respondents will receive a $5 Amazon gift card. Take the survey now.

So far, Januvia has weathered competition from Lilly and Boehringer Ingelheim's SGLT2 med Jardiance, which showed last year that it could cut cardiovascular risks, including heart attack and death. In second-quarter results, the Merck franchise brought in a consensus-beating $1.63 billion. But analysts still worry that the aging Januvia franchise may falter.

It's not just new rivalries that are heightening the strain on Januvia--and other diabetes meds, for that matter. They face increased pricing pressure from payers, too. Those pressures, along with rising drug costs for payers, have made drugmakers and insurers willing to test results-based setups. Apart from Eli Lilly, Merck joins companies including Novartis, Amgen, Regeneron and Sanofi to sign on with payers for performance-based plans.

Aetna has been active on the front, inking a deal with Novartis for the heart failure med Entresto. Under that deal, rebates depend on whether Entresto delivers real-world results similar to those in trials. Novartis inked a similar performance-based deal with Cigna.

Amgen, Regeneron and Sanofi each paired with payers for their next-gen cholesterol fighters in an effort to grow uptake. Amgen signed on with Harvard Pilgrim and Cigna with its Repatha, while Sanofi and Regeneron paired with Cigna on Praluent.

Along with the results-based Januvia deal, Aetna and Merck also unveiled AetnaCare, a “predictive analytics” platform to target wellness services toward individual patients. Merck will provide some of its previously developed educational resources and tools for the program.

Related Articles:
Most U.S. payers are eyeing outcomes-based drug pricing: Report
Lilly's Trulicity joins pay-for-performance trend with Harvard Pilgrim deal
Januvia holds off SGLT2s to keep Merck's Q2 in line
Novartis defies naysayers with newfangled pay-for-performance deals on Entresto
Cigna inks results-based deals on pricey Amgen, Sanofi PCSK9 meds​
Surprise proposal: Medicare wants to jump on the value-based pricing bandwagon
Novartis, Roche CEOs see performance-based future, but U.S. isn't ready yet

Suggested Articles

An injection that's under FDA priority review as a monthly HIV therapy can suppress the virus even if given every two months, a phase 3 has shown.

Pfizer and Astellas are chasing a new nod for prostate cancer drug Xtandi, and thanks to the FDA, they might not have to wait that long.

Sanofi lost an appeal challenging the ban on its dengue vaccine Dengvaxia in the Philippines, despite an ongoing outbreak there.